<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185002</url>
  </required_header>
  <id_info>
    <org_study_id>MA-111</org_study_id>
    <nct_id>NCT01185002</nct_id>
  </id_info>
  <brief_title>Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen</brief_title>
  <official_title>Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Given Imaging Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Given Imaging Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the effect of a bowel preparation and boosts regimen on
      PillCam® procedure, colon cleanliness and capsule excretion time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interim analysis will be done after 20 subjects are enrolled in order to assess the 1st arm.
      Following the analysis of the first phase results, and per need, 30 more subjects may be
      enrolled under a different regimen (2nd arm). Second Interim analysis will be done in order
      to assess the 2nd phase results. Following the analysis of the 2nd phase results, and per
      need, up to 30 additional subjects may be enrolled under a third regimen (3rd arm).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Capsule excretion rate</measure>
    <time_frame>10 hours post capsule ingestion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of PillCam® COLON 2 excretion times</measure>
    <time_frame>Up to 12 hours and at least 12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colonoscopy</condition>
  <condition>Endoscopy</condition>
  <arm_group>
    <arm_group_label>MgC boosts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.
In this arm the subjects will be administered MgC boosts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suprep boosts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.
In this arm the subjects will be administered Suprep boosts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suprep boosts - Reduced dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.
In this arm the subjects will be administered a reduced dose of Suprep boosts</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PillCam® COLON 2 procedure using MgC boosts</intervention_name>
    <description>Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.</description>
    <arm_group_label>MgC boosts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PillCam® COLON 2 procedure using Suprep boosts</intervention_name>
    <description>Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts</description>
    <arm_group_label>Suprep boosts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PillCam® COLON 2 procedure using reduced dose of Suprep boosts</intervention_name>
    <description>Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts</description>
    <arm_group_label>Suprep boosts - Reduced dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is between 50 - 75 years of age.

          2. Subject received an explanation about the nature of the study and agrees to provide
             written informed consent.

        Exclusion Criteria:

          1. Subject has dysphagia or any swallowing disorder

          2. Subject has congestive heart failure

          3. Subject has Diabetes type I.

          4. Subject has had prior abdominal surgery other than uncomplicated procedures that would
             be unlikely to lead to bowel obstruction based on the clinical judgment of the
             investigator

          5. Subject has a cardiac pacemaker or other implanted electro medical device.

          6. Subject has any allergy or other known contraindication to the medications used in the
             study

          7. Subject is expected to undergo MRI examination within 7 days after ingestion of the
             capsule.

          8. Subject with any condition believed to have an increased risk for capsule retention
             such as Crohn's disease, intestinal tumors, radiation enteritis, and incomplete
             colonoscopies due to obstructions or NSAID enteropathy.

          9. Subject with gastrointestinal motility disorders

         10. Subject has known delayed gastric emptying

         11. Subject has any condition, which precludes compliance with study and/or device
             instructions.

         12. Women who are either pregnant or nursing at the time of screening, or are of
             child-bearing potential and do not practice medically acceptable methods of
             contraception.

         13. Subject suffers from life threatening conditions

         14. Subject currently participating in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Rex, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastroenterology Indiana University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Digestive Disorders Center</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Associates of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Division of Digestive Disease</name>
      <address>
        <city>Chapel Hill,</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Care, Inc.</name>
      <address>
        <city>Beavercreek</city>
        <state>Ohio</state>
        <zip>45440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Gastroenterology</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Tidewater</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.givenimaging.com/en-us/Pages/GivenWelcomePage.aspx</url>
    <description>Given Imaging Website</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hilla Debby / Director of Clinical Affaris</name_title>
    <organization>Given Imaging Ltd.</organization>
  </responsible_party>
  <keyword>CE</keyword>
  <keyword>colonoscopy</keyword>
  <keyword>colon</keyword>
  <keyword>Eligable for colon evaluation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

